Alaunos Therapeutics Inc (TCRT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Alaunos Therapeutics Inc stock (TCRT) is currently trading at $3.01. Alaunos Therapeutics Inc PS ratio (Price-to-Sales) is 1167.99. Analyst consensus price target for TCRT is $1.75. WallStSmart rates TCRT as Sell.
- TCRT PE ratio analysis and historical PE chart
- TCRT PS ratio (Price-to-Sales) history and trend
- TCRT intrinsic value — DCF, Graham Number, EPV models
- TCRT stock price prediction 2025 2026 2027 2028 2029 2030
- TCRT fair value vs current price
- TCRT insider transactions and insider buying
- Is TCRT undervalued or overvalued?
- Alaunos Therapeutics Inc financial analysis — revenue, earnings, cash flow
- TCRT Piotroski F-Score and Altman Z-Score
- TCRT analyst price target and Smart Rating
Alaunos Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Alaunos Therapeutics Inc (TCRT) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Alaunos Therapeutics Inc (TCRT) Key Strengths (2)
Growing significantly faster than its price suggests
Revenue surging 100.00% year-over-year
Alaunos Therapeutics Inc (TCRT) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 1168.0x annual revenue
Very low institutional interest at 6.37%
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
Alaunos Therapeutics Inc (TCRT) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Revenue Growth. Valuation metrics including PEG Ratio (0.58) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 100.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (1167.99), Price/Book (2.56) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -145.60%, Operating Margin at -67883.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -145.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 100.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TCRT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TCRT's Price-to-Sales ratio of 1167.99x trades 865% above its historical average of 121.07x (94th percentile), historically expensive. The current valuation is 30% below its historical high of 1678.31x set in Jul 2024, and 2335880% above its historical low of 0.05x in Nov 2023.
WallStSmart Analysis Synopsis
Data-driven financial summary for Alaunos Therapeutics Inc (TCRT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Alaunos Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 6,000 with 100% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 100% YoY, reaching 6,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 7817% of revenue (469,000) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -941,000, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Alaunos Therapeutics Inc maintain 100%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Alaunos Therapeutics Inc.
Bottom Line
Alaunos Therapeutics Inc is a high-conviction growth story with revenue accelerating at 100% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Alaunos Therapeutics Inc(TCRT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.